CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionFranklin Resources Inc
Latest Disclosed Ownership28,381 shares
Latest Disclosed Value $ 1,350,084
Franklin Resources Inc reports 15.62% increase in ownership of CRSP / CRISPR Therapeutics AG

On May 13, 2026 - Franklin Resources Inc filed a 13F-HR form disclosing ownership of 28,381 shares of CRISPR Therapeutics AG (US:CRSP) valued at $1,350,084 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 24,546 shares of CRISPR Therapeutics AG. This represents a change in shares of 15.62% during the quarter. The current value of the position is $1,616,298 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 28,381 3,835 15.62 1,350 4.90 0.0001
2026-02-11 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,546 -1,271 -4.92 1,287 -23.07 0.0003
2025-11-13 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 25,817 18,217 239.70 1,673 353.39 0.0004
2025-08-12 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 7,600 165 2.22 370 45.85 0.0001
2025-05-13 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 7,435 429 6.12 253 -8.00 0.0001
2025-02-12 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 7,006 -91 -1.28 276 -18.88 0.0001
2024-11-27 2024-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 7,097 800 12.70 339 -0.29 0.0001
2024-11-12 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 7,097 800 339 0.0000
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 6,297 23 0.37 340 -20.37 0.0001
2024-05-13 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 6,274 319 5.36 428 14.78 0.0001
2024-02-09 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,955 -227,444 -97.45 373 -96.49 0.0002
2023-11-13 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 233,399 201 0.09 10,594 -19.08 0.0054
2023-08-11 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 233,198 35 0.02 13,092 24.14 0.0062
2023-05-12 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 233,163 -60,908 -20.71 10,546 -11.78 0.0053
2023-02-10 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 294,071 -1,901 -0.64 11,954 -38.20 0.0062
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 295,972 3,326 1.14 19,341 8.76 0.0105
2022-08-11 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 292,646 -313 -0.11 17,784 -3.29 0.0088
2022-05-13 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 292,959 -19,544 -6.25 18,389 -22.35 0.0073
2022-02-11 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 312,503 -6,712 -2.10 23,681 -33.72 0.0085
2021-11-12 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 319,215 2,525 0.80 35,730 -30.31 0.0135
2021-08-13 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 316,690 -512,664 -61.81 51,268 -49.27 0.0196
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 829,354 4,292 0.52 101,056 -20.00 0.0411
2021-02-10 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 825,062 -76,751 -8.51 126,325 67.48 0.0535
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 901,813 2,292 0.25 75,427 -9.81 0.0365
2020-08-13 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 899,521 456,574 103.08 83,629 345.19 0.0431
2020-05-13 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 442,947 7,303 1.68 18,785 -29.20 0.0125
2020-03-11 2019-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 435,644 11,031 2.60 26,533 52.44 0.0139
2020-02-12 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 435,644 11,031 26,533 3,351.4812
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 424,613 0 0.00 17,405 -12.97 0.0095
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 424,613 0 0.00 20,000 31.87 0.0106
2019-05-15 2019-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 424,613 -54,750 -11.42 15,167 10.74 0.0081
2019-05-14 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 424,613 -54,750 15,167
2019-02-12 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 479,363 0 0.00 13,696 -35.58 0.0083
2018-11-13 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 479,363 -242,420 -33.59 21,259 -49.88 0.0106
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 721,783 10,050 1.41 42,412 30.36 0.0218
2018-05-10 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 711,733 -82,800 -10.42 32,534 74.39 0.0165
2018-02-14 2017-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 794,533 65,200 8.94 18,656 43.14 0.0090
2017-11-13 2017-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 729,333 0 0.00 13,033 11.55 0.0064
2017-08-10 2017-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 729,333 0 0.00 11,684 -25.76 0.0058
2017-05-12 2017-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 729,333 0 0.00 15,738 9.38 0.0080
2017-02-14 2016-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 729,333 729,333 14,389 0.0074
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.